New combo therapy offers hope for Hard-to-Treat leukemia patients
NCT ID NCT07635485
First seen Jun 10, 2026 · Last updated Jun 15, 2026 · Updated 1 time
Summary
This study tests a two-step approach for adults with a rare or treatment-related form of acute myeloid leukemia (AML). First, patients receive a combination of two drugs (venetoclax and azacitidine) to reduce cancer cells. Then, they receive a stem cell transplant from a donor to rebuild a healthy blood system. The goal is to see if this approach helps people live longer and achieve remission. About 50 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.